Taro Pharmaceutical Industries Ltd
F:TAL

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
F:TAL
Watchlist
Price: 40 EUR 1.01% Market Closed
Market Cap: €1.5B

Gross Margin

57%
Current
Improving
by 6.3%
vs 3-y average of 50.7%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57%
=
Gross Profit
$305m
/
Revenue
$629.2m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57%
=
Gross Profit
€305m
/
Revenue
$629.2m

Peer Comparison

Country Company Market Cap Gross
Margin
IL
Taro Pharmaceutical Industries Ltd
F:TAL
1.5B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 75% of companies in Israel
Percentile
75th
Based on 676 companies
75th percentile
57%
Low
-11 239.1% — 17.6%
Typical Range
17.6% — 50.4%
High
50.4% — 208.2%
Distribution Statistics
Israel
Min -11 239.1%
30th Percentile 17.6%
Median 29.8%
70th Percentile 50.4%
Max 208.2%

Taro Pharmaceutical Industries Ltd
Glance View

Market Cap
1.5B EUR
Industry
Pharmaceuticals

In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.

TAL Intrinsic Value
Not Available
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
57%
=
Gross Profit
$305m
/
Revenue
$629.2m
What is Taro Pharmaceutical Industries Ltd's current Gross Margin?

The current Gross Margin for Taro Pharmaceutical Industries Ltd is 57%, which is above its 3-year median of 50.7%.

How has Gross Margin changed over time?

Over the last 3 years, Taro Pharmaceutical Industries Ltd’s Gross Margin has decreased from 63.4% to 57%. During this period, it reached a low of 47.6% on Jun 30, 2023 and a high of 63.4% on Jun 30, 2021.

Back to Top